Reversine exhibits antineoplastic activity in JAK2 V617F -positive myeloproliferative neoplasms

• Published in: Scientific reports Vol. 9; no. 1; p. 9895
• Main Authors: Lima, Keli, Carlos, Jorge Antonio Elias Godoy, Alves-Paiva, Raquel de Melo, Vicari, Hugo Passos, Souza Santos, Fábio Pires de, Hamerschlak, Nelson, Costa-Lotufo, Leticia Veras, Traina, Fabiola, Machado-Neto, João Agostinho
• Format: Journal Article
• Language: English
• Published: England 09.07.2019
• Subjects: Apoptosis; Aurora Kinase A - genetics; Aurora Kinase A - metabolism; Aurora Kinase B - genetics; Aurora Kinase B - metabolism; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Cell Cycle; Cell Proliferation; Gene Expression Regulation, Neoplastic - drug effects; Humans; Janus Kinase 2 - genetics; Janus Kinase 2 - metabolism; Morpholines - pharmacology; Mutation; Myeloproliferative Disorders - genetics; Myeloproliferative Disorders - metabolism; Myeloproliferative Disorders - pathology; Protein Kinase Inhibitors; Purines - pharmacology; Tumor Cells, Cultured

JAK2/STAT signaling participates in the Ph-negative myeloproliferative neoplasms (MPN) pathophysiology and has been targeted by ruxolitinib, a JAK1/2 inhibitor. In the present study, the impact of ruxolitinib treatment on cytoskeleton-related genes expression was explored. In SET2 cells, AURKA and AURKB expression/activity were downregulated in a dose- and time-dependent manner by ruxolitinib. Reversine, a multikinase inhibitor selective for aurora kinases, reduced cell viability in a dose- and/or time-dependent manner in JAK2 cells. Reversine significantly increased apoptosis and mitotic catastrophe, and reduced cell proliferation and clonogenic capacity in SET2 and HEL cells. In the molecular scenario, reversine induced DNA damage and apoptosis markers, as well as, reduced AURKA and AURKB expression/activity. In SET2 cells, reversine modulated the expression of 32 out of 84 apoptosis-related genes investigated, including downregulation of antiapoptotic (BCL2, BCL2L1, and BIRC5) and upregulation of proapoptotic (BIK, BINP3, and BNIP3L) genes. Synergism experiments indicated that low dose of reversine had a potentiating effect under ruxolitinib treatment at low doses in SET2 cells. In summary, our exploratory study establishes new targets, related to the regulation of the cellular cytoskeleton, for potential pharmacological intervention in MPN. These findings indicate that AURKA and AURKB participate in the JAK2/STAT signaling pathway and contribute to the MPN phenotype.